SMMT Q1 2024 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$27,000

Operating Income

-$42M

Net Income

-$43M

EPS (Diluted)

$-0.06

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$177M

Total Liabilities

$133M

Stockholders' Equity

$44M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$27,000	$0	—
Operating Income	-$42M	-$537M	+92.1%
Net Income	-$43M	-$542M	+92.0%